The state of Idaho currently has 22 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Boise, Meridian, Idaho Falls and Nampa.
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study that consists of 2 parts. In Part A the safety of the highest dose-level of frexalimab in adults (age range 18-35 y.o.) will be established. In Part B, a dose-finding study (adolescents and young adults, 12-21 y.o.) evaluating the safety and efficacy of 3 age-adjusted dose-levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. The purpose of this study is to determine safety a... Read More
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
02/22/2024
Locations: Rocky Mountain Diabetes and Osteoporosis Center Site Number : 8400009, Idaho Falls, Idaho
Conditions: Type 1 Diabetes Mellitus
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Recruiting
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar levels as compared to insulin glargine in people with type 2 diabetes who do not have their blood sugar properly controlled with other oral diabetes medicines. Participant will either get IcoSema or insu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Elite Clinical Trials, Blackfoot, Idaho
Conditions: Type 2 Diabetes
Afrezza® INHALE-1 Study in Pediatrics
Recruiting
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine in combination with a basal insulin (i.e., the Rapid-acting Insulin Analog [RAA] injection group) in pediatric subjects with type 1 or type 2 diabetes mellitus. Following 26 weeks of randomized treatment (i.e., Afrezza or RAA injection combined with a basal insulin), all... Read More
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
02/22/2024
Locations: Rocky Mountain Clinical Research, Idaho Falls, Idaho
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: Solaris Clinical Research, Meridian, Idaho
Conditions: Obesity, Diabetes Mellitus, Type 2
Diamyd Administered Into Lymph Nodes in Individuals Recently Diagnosed With Type 1 Diabetes, Carrying the HLA DR3-DQ2 Haplotype
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
All
Ages:
Between 12 years and 28 years
Trial Updated:
02/16/2024
Locations: Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases, Immune System Disease, Diabetes, Juvenile Diabetes, Endocrine System Diseases, Insulin Dependent Diabetes Mellitus 1, Glucose Metabolism Disorders, Metabolic Disease, Autoimmune Diabetes, Dysglycemia
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: St. Luke's Health System, Boise, Idaho +1 locations
Conditions: Type 2 Diabetes Mellitus
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
Recruiting
The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS). Participants will be asked to: Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2024
Locations: Rocky Mountain Clinical Research, Idaho Falls, Idaho
Conditions: Type1diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/11/2024
Locations: St. Luke's Health System, Boise, Idaho +1 locations
Conditions: Type 2 Diabetes
A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes
Recruiting
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Rocky Mountain Clinical Research, Idaho Falls, Idaho
Conditions: Type 2 Diabetes Treated With Insulin
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Recruiting
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Bingham Memorial Hospital, Blackfoot, Idaho +1 locations
Conditions: Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Recruiting
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Elite Clinical Trials, Rexburg, Idaho
Conditions: Type 2 Diabetes
Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Dail... Read More
Gender:
All
Ages:
Between 2 years and 80 years
Trial Updated:
01/18/2024
Locations: Rocky Mountain Diabetes, Idaho Falls, Idaho
Conditions: Type 1 Diabetes